Portugal - Portugis - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

aj vaccines a/s - tuberculina - solução injetável - 0.0004 mg/ml - tuberculina 0.0004 mg/ml - tuberculin - n/a - duração do tratamento: curta ou média duração

Portugal - Portugis - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

merck sharp & dohme, lda. - vacina pneumocócica poliosídica - solução injetável - associação - polissacárido s. pneumoniae (ser. 1,2,3,4,5,6b,7f,8,9n,9v,10a,11a,12f,14,15b,17f,18c,19f,19a,20,22f,23f,33f) 1.15 mg/ml - pneumococcus, purified polysaccharides antigen - vacina - duração do tratamento: curta ou média duração

Portugal - Portugis - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

merck sharp & dohme, lda. - vacina pneumocócica poliosídica - solução injetável - associação - polissacárido s. pneumoniae (ser. 1,2,3,4,5,6b,7f,8,9n,9v,10a,11a,12f,14,15b,17f,18c,19f,19a,20,22f,23f,33f) 1.15 mg/ml - pneumococcus, purified polysaccharides antigen - vacina - duração do tratamento: curta ou média duração

Kesatuan Eropah - Portugis - EMA (European Medicines Agency)

seqirus s.r.l.  - zoonotic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted), influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) - influenza a virus, h5n1 subtype - vacinas - active immunisation against h5 subtype of influenza a virus.

Kesatuan Eropah - Portugis - EMA (European Medicines Agency)

pfizer limited - pneumococcal oligosaccharide serotype 18c, pneumococcal polysaccharide serotype 19f, pneumococcal polysaccharide serotype 23f, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 14 - pneumococcal infections; immunization - vacinas - imunização ativa contra doenças causadas por sorotipos de streptococcus pneumoniae 4, 6b, 9v, 14, 18c, 19f e 23f (incluindo sepsis, meningite, pneumonia, bacteremia e otite média aguda) em lactentes e crianças de dois meses até cinco anos de idade. o uso de prevenar deve ser determinada com base nas recomendações oficiais, levando em consideração o impacto da doença invasiva em diferentes grupos de idade, bem como a variabilidade do subtipo epidemiologia em diferentes áreas geográficas.

Brazil - Portugis - CPVS (Compêndio de Produtos Veterinários)

mcassab comÉrcio e indÚstria ltda. - oxitetraciclina; - antimicrobianos gerais; antifÚngicos e antiprotozoÁrios (coccidios, flagelados)

Kesatuan Eropah - Portugis - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - porcos - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Kesatuan Eropah - Portugis - EMA (European Medicines Agency)

zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - imunológicos para suidae - suínos (para engorda) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d. active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection.  onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination.  duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination.  in addition, vaccination has been shown to reduce body weight gain losses under field conditions.

Portugal - Portugis - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

pharmakern portugal - produtos farmacêuticos, sociedade unipessoal, lda. - diclofenac - gel - 20 mg/g - diclofenac, dietilamónio 23.2 mg/g - diclofenac - n/a - duração do tratamento: curta ou média duração

Portugal - Portugis - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

generis farmacêutica, s.a. - topiramato - comprimido revestido por película - 25 mg - topiramato 25 mg - topiramate - genérico - duração do tratamento: longa duração